



FOR IMMEDIATE RELEASE
November 14, 2007

IMRIS INC. REPORTS SIGNIFICANT GROWTH IN SALES AND ORDER BACKLOG

*IPO proceeds to fund expansion of IMRISneuro
and product development initiatives*

WINNIPEG, Manitoba, November 14, 2007 - IMRIS Inc. (TSX: IM) ("IMRIS" or the "Company") today reported its financial results for the third quarter and nine months ended September 30, 2007.

Summary:

- Significant sales growth due to increase in IMRISneuro installations
- Order backlog rose 46% year-over-year to \$28.4 million
- Gross profit percentage decreased year-over-year primarily due to establishment of demonstration sites as part of commercialization strategy
- Net loss increased year-over-year primarily due to increased staff levels as part of commercialization strategy
- Gross proceeds of \$40 million raised from oversubscribed IPO completed November 2, 2007

"IMRIS' strong sales and growth in our order backlog reflect our products' increasing market acceptance," said David Graves, Chairman, President and Chief Executive Officer. "We are also extremely pleased to have added our first two international customers in the quarter, one in India and one in China."

He added, "The recent completion of our IPO marks a new and exciting phase in IMRIS' evolution. It will allow us to further the commercialization of our IMRISneuro products and proceed with the development of additional applications for our core technology, thereby opening new markets for the Company. We expect that our order backlog will continue to grow as we expand our addressable markets and secure more agreements with leading hospitals around the world."

Selected Financial Highlights
(in CDN dollars)
(unaudited)

	Third Quarter Ended Sep 30		% Change	Nine Months Ended Sep 30		% Change
	2007	2006		2007	2006	
Sales	7,969,788	379,112	2002%	14,020,667	738,157	1799%
Gross Profit	702,446	99,521	606%	1,797,620	149,389	1103%
Gross Profit Percentage	8.8%	26.3%		12.8%	20.2%	
Operating Expenses	3,928,367	2,458,342	60%	12,086,746	6,130,640	97%
Net Income (Loss)	(3,459,339)	(2,363,269)	46%	(10,501,025)	(6,181,738)	70%
Net Income (Loss) per basic and fully diluted share	(0.20)	(0.20)		(0.59)	(0.53)	

Third Quarter and Nine-Month Results

Sales were \$8.0 million for the third quarter and \$14.0 million for the nine-month period, representing increases of \$7.6 million and \$13.3 million respectively compared to the same periods last year. These increases were attributable to an increase in IMRISneuro system installations. During the nine-month period, IMRIS had four systems in various phases of installation versus one system installation having been started in the previous year.

Gross profit was \$0.7 million for the third quarter and \$1.8 million for the nine-month period, representing increases of \$0.6 million and \$1.6 million respectively compared to the same periods last year. These increases were attributable to the ramp-up in system installations detailed above.


Gross profit as a percentage of sales was 8.8% for the third quarter and 12.8% for the nine-month period compared to 26.3% and 20.2% respectively for the same periods last year. These decreases in gross profit percentage were primarily due to discounted prices provided to two strategic customers who have agreed to act as demonstration and visitation sites for the Company's prospective customers, as well as a \$1.0 million non-product related cost to provide room finishes to one of these sites. These demonstration installations include a leading adult neurological centre and a leading pediatric hospital and will provide IMRIS with highly credible reference sites for showcasing the IMRISneuro product.

Operating expenses were \$3.9 million for the third quarter and \$12.1 million for the nine-month period, representing increases of \$1.5 million and \$6.0 million respectively compared to the same periods last year. The increases were reflected across all major functional areas of the Company, including administration, customer support and operations, research and development, and sales and marketing. A substantial amount of the increases in these departmental expenses was attributable to increased staffing levels as the Company continues to build organizational capacity across all functional areas.

The net loss was \$3.5 million for the third quarter and \$10.5 million for the nine-month period, representing increases of \$1.1 million and \$4.3 million respectively compared to the same periods last year. On a basic and diluted share basis, the net loss was \$0.20 for the third quarter and \$0.59 for the nine-month period. These compare to net losses of \$0.20 and \$0.53 per basic and diluted share respectively for the same periods last year. The increases were principally due to increased staff levels to facilitate the Company's increased commercialization efforts.

Outlook

Order Backlog



As at September 30, 2007, IMRIS' order backlog totaled \$28.4 million, an increase of 46% from the previous year. This order backlog includes orders for two systems that are partially installed and expected to be completed in the fourth quarter of 2007 and six units that are scheduled for delivery in 2008.

Due to IMRIS being in an early growth stage and the high dollar value associated with each system sale, quarter-over-quarter revenue may vary depending on the number and nature of active projects during any given period. However, management expects overall sales and gross margin to continue to grow on an annualized basis due to the Company's growing order backlog.

"IMRIS' outlook is positive based on the strength of our current order backlog as well as our order prospects," said Mr. Graves. "Our immediate priorities are to efficiently complete customer installations on hand, convert our promising

prospects into new orders and aggressively tackle our stated technology and market development initiatives.”

The Company’s full financial statements as well as management’s discussion and analysis are available at www.sedar.com and www.imris.com.

Conference Call

Management will host a conference call to discuss the results at **10 a.m. ET** (9 a.m. CT) on **Wednesday, November 14, 2007**. Following management’s presentation, there will be a question and answer session for analysts and institutional investors. To participate in the teleconference, please call **416-644-3428** or **1-800-590-1817**. To access the live audio webcast, please visit IMRIS’ website at www.imris.com. A taped rebroadcast will be available to listeners following the call until midnight (ET) on Wednesday, November 21, 2007. To access the rebroadcast, please call 416-640-1917 or 1-877-289-8525 and enter passcode 21252722#. The webcast will also be archived on IMRIS’ website.

About IMRIS

IMRIS is a global leader in surgical imaging solutions designed to improve patient outcomes and help them live longer and more enjoyable lives. IMRIS’ key technology benefits of high resolution MR images, improved patient safety, enhanced surgical efficiency and increased financial viability for hospitals contribute to a breakthrough surgical imaging offering. The Company’s lead product, IMRISneuro, has been validated by leading U.S. neurosurgeons and is increasingly being used by world-class neuroscience centres. IMRIS core MRI technology has multiple product applications with a second product suite, IMRIScardio, which is under active development.

See www.imris.com

Forward-Looking Statements

This press release may contain or refer to forward-looking information based on current expectations. These statements should not be understood as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, there can be no assurance that actual results will be consistent with such statements. Forward-looking statements are subject to significant risks and uncertainties, and other factors that could cause actual results to differ materially from expected results. These forward-looking statements are made as of the date hereof and we assume no responsibility to update or revise them to reflect new events or circumstances.

-- 30 --

For further information:

Ron Sabourin
Executive Vice President, Finance
and Chief Financial Officer
IMRIS Inc.
Tel: 204-480-7090
Email: rsabourin@imris.com

Susan McLeod
Manager, Marketing
Communications
IMRIS Inc.
Tel: 204-480-7094
Email: smcleod@imris.com